1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
1260MO OSE-2101 在 HLA-A2+ 非小细胞肺癌 (NSCLC) 患者中免疫检查点抑制剂 (ICI) 治疗失败后的活性:III 期 ATALANTE-1 随机试验的第一阶段结果
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2022.09.153
Pradier, A; Mamez, A C; Stephan, C; Giannotti, F; Masouridi-Levrat, S; Wang, S; Morin, S; Neofytos, D; Vu, D L; Melotti, A; Arm, I; Eberhardt, C S; Tamburini, J; Kaiser, L; Chalandon, Y; Simonetta, F; Bakouny, Z; Grover, P; Labaki, C; Awosika, J; Gulati, S; Hsu, C-Y; Bilen, MA; Eton, O; Fecher, L; Hwang, C; Khan, H; McKay, RR; Ruiz, E; Weissmann, L; Thompson, MA; Shah, D; Warner, J; Shyr, Y; Choueiri, TK; Wise-Draper, T; Pacheco-Barcia, V; Sanchez, DA; Obispo, B; Quilez, A; Sesma, A; JimEnez Labaig, P; Paez, D; Quintanar Verduguez, T; Sánchez Cánovas, M; Tarazona, N; Fernandez Montes, A; Felip, E; Rodríguez-Lescure, A; Elez Fernandez, ME; Giaccone, G; Felip, E; Cobo, M; Campelo, R Garcia; DENIS, F; Quoix, E; Madroszyk, A; Debieuvre, D; Hilgers, W; Moran, T; Galetta, D; Romano, GD; Cappuzzo, F; Robinet, G; Masson, P; Viteri, S; Peled, N; Costantini, D; Dziadziuszko, R; Besse, B